The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

Vertex Pharmaceuticals (VRTX ... to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988.

Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...

However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

Vertex Pharmaceuticals (VRTX ... suggest that it may perform in line with the broader market in the near term. History suggests their performance could be sensational. From 2012 (when our Director ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Vertex Pharmaceuticals (VRTX ... to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988.

We noticed this today when the trades showed up on publicly available options history that we track ... spotted 13 uncommon options trades for Vertex Pharmaceuticals. This isn't normal.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... Consider more frequent monitoring for patients with a history of liver disease or elevated liver function tests (LFTs) at baseline.